Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials

IMPORTANCE: Immune checkpoint inhibitors have demonstrated atypical response patterns, which may not be fully captured by conventional response criteria. There is a need to better understand the potential benefit of continued immune checkpoint inhibition beyond progression. OBJECTIVE: To evaluate th...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Oncol
Autori principali: Long, Georgina V., Weber, Jeffrey S., Larkin, James, Atkinson, Victoria, Grob, Jean-Jacques, Schadendorf, Dirk, Dummer, Reinhard, Robert, Caroline, Márquez-Rodas, Ivan, McNeil, Catriona, Schmidt, Henrik, Briscoe, Karen, Baurain, Jean-François, Hodi, F. Stephen, Wolchok, Jedd D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2017
Soggetti:
Original Investigation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5710191/
https://ncbi.nlm.nih.gov/pubmed/28662232
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.1588
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi